You are here

ESP1 / SARC025

Active
ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide or Irinotecan in Patients With Previously Treated, Incurable Ewing Sarcoma
Type of Sarcoma: 
Ewing Sarcoma
Drug: 
Niraparib, Temozolomide and Irinotecan
Accrual Status: 
Not Recruiting
Overall Study Principal Investigator: 
Sandra Strauss, MBBS, PhD
Senior Lecturer and Consultant Medical Oncologist
University College London, Cancer Institute

Rashmi Chugh, MD
Assistant Professor
University of Michigan

For more information about this trial and open sites: